Nazca acquires a majority stake in Diater, pioneer in immunotherapy treatments for allergy, in a deal valued at €45 million

by Nazca Capital

NAZCA CAPITAL –one of the leading mid-market private equity funds in Spain– has reached an agreement (through Nazca Fund IV) with Ferrer to acquire its stake in DIATER, a Spanish biopharmaceutical...

Read more
Subscribe to Directory
Write an Article

Highlight

Axon moves into Cloud Technology

by Axon Partners Group

cloud technology axon

The return of the IPO market: a necessar...

by Qualitas Funds

Importantly, the significance of IPO markets extends beyond the compan...

Photos Stream